Shannon Connelly

Evan Y. Yu, MD, discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.

Emma L. Barber, MD, discusses her research into neoadjuvant chemotherapy for ovarian cancer and its effect on hospital readmission rates.

James B. Yu, MD, discusses the current data in support of using moderate hypofractionation in prostate cancer, as well as recent data showing how genomic testing can help with treatment decision making postoperatively.

Arjun Balar, MD, discusses the treatment considerations he makes when treating patients with urothelial carcinoma, the role of PD-L1 tumor expression and immune checkpoint inhibitors, and the potential for new immunotherapy agents in this space.

Ursula A. Matulonis, MD, discusses results of the phase III NOVA trial showed the PARP inhibitor niraparib demonstrated an improvement in PFS versus placebo as a maintenance therapy for patients with high-grade serous ovarian cancer.

Alon Altman, MD, discusses a study that examined the effects of number of neoadjuvant chemotherapy cycles on patient outcomes.

Evanthia Galanis, MD, discusses the issues that currently exist in clinical trial design in oncology and neuro-oncology, as well as how they can be addressed.

Engaging in moderate physical activity daily was shown to reduce mortality and cancer progression in patients with metastatic colorectal cancer.

Genetic counselor Krista Qualmann, MS, CGC, discusses the syndromes she is identifying in patients in her clinic, as well as how they could impact brain tumor treatment.

The use of tumor treating fields as a treatment for patients with brain tumors has, thus far, largely been focused on in glioblastoma, but an upcoming trial aims to expand the use of the device to the grade III patient population, says Daniel O’Connell, MD.

Cristina Gasparetto, MD, discuss treatment considerations and options for patients with multiple myeloma based on 2 case scenarios.

In a recent early-stage HER2-positive breast cancer trial, prophylactic treatment with the combination of loperamide and budesonide reduced the rate of grade 3 diarrhea associated with neratinib to 15%.

Nancy Gordon, MD, speaks about her osteosarcoma research, the next steps following the findings of the study, and what she envisions for the treatment landscape of osteosarcoma over the next decade.

The FDA has approved the marketing of AeroForm, a new system for soft tissue expansion in 2-stage breast reconstruction following mastectomy, and in the treatment of underdeveloped breasts and soft tissue deformities.

In an interview with <em>Targeted Oncology</em>, Howard Fine discusses the reason for renewed interested in metabolic targets, the effect it has had on treatment of gliomas, and what he sees on the horizon for neuro-oncology in this area.<br /> &nbsp;

Jared Weiss, MD, recently sat down with&nbsp;<em>Targeted Oncology</em>&nbsp;to discuss treatment considerations and options for patients with metastatic lung cancer based on 3 case scenarios.

The 2017 Miami Breast Cancer Conference, to be held March 9 to 12 at the Fontainebleau Miami Beach, welcomes an expanded group of program chairs, and a newly established curriculum committee made up of a multidisciplinary group of breast cancer specialists.

Michael Morse, MD, discusses treatment considerations and options for 2 cases of patients with colorectal cancer

Jeffery S. Weber, MD, PhD, discusses treatment considerations and options for 3 cases of patients with metastatic melanoma.

Researchers are currently investigating the use of tropomyosin receptor kinase (TRK) inhibitor entrectinib (RXDX-101) to treat patients with relapsed or refractory solid tumors or primary tumors of the central nervous system.

Breelyn Wilky, MD, recently sat down <em>Targeted Oncology</em> to discuss recent findings of a trial investigating axitanib and pembrolizumab in soft tissue sarcomas, as well as the role she envisions for immunotherapy in the treatment of sarcoma.

Raoul Concepcion, MD, director, Comprehensive Prostate Center, recently sat down with <em>Targeted Oncology </em>to discuss his treatment decisions for 2 patient scenarios in prostate cancer.

If an overall survival advantage is found for patients receiving first-line FOLFOX6 with or without bevacizumab plus Yttrium-90 resin microspheres for liver metastatic colorectal cancer.

Nationally recognized oncologist Nancy E. Davidson, MD, has accepted the position of Executive Director of Clinical Oncology at the Fred Hutch/University of Washington (UW) Cancer Consortium in Seattle, Washington. Davidson was previously Director of the the University of Pittsburgh Cancer Institute (UPCI).

Rimas Lukas, MD, discusses the next steps in glioblastoma research, as well as the potential use of IDO inhibitors in the treatment of GBM, and recent studies showing promise in the field.

Steve Coutre, MD, discusses how he determines which CLL treatment option is best for which patient, the advantage of treating patients with ibrutinib over chemoimmunotherapy, and new oral agents currently being investigated in the space.

Lori Rink, PhD, speaks about what oncologists have learned about GIST in the past 3 decades, the important role of imatinib mesylate (Gleevec) in treating the disease, and the personalized treatment approach on the horizon.

Haifa Kathrin Al-Ali, MD, and Carlos Besses, MD, PhD debated the need for new drugs to treat&nbsp;polycythemia vera (PV) and essential thrombocythemia (ET).&nbsp;

Goals of &quot;Project Impact: A Campaign to Defeat Pediatric Brain Tumors&quot;&nbsp;include improving clinical outcomes for pediatric brain tumor patients and informing the development of the first-ever standard of care for treating pediatric high-grade gliomas.

As therapeutic approaches with more efficacy and less toxicity are still highly needed, researchers are currently working to identify new targets in the MB field.